Ultragenyx Pharmaceutical Inc.
RARE
$21.34
-$0.37-1.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.05% | -3.70% | 8.95% | 10.43% | 6.20% |
| Total Depreciation and Amortization | -2.78% | 3.08% | 8.41% | 22.05% | 38.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.62% | -2.06% | -5.20% | 2.12% | -13.17% |
| Change in Net Operating Assets | -264.29% | -116.89% | -5.22% | 140.87% | 192.71% |
| Cash from Operations | -12.56% | -6.43% | 10.31% | 23.38% | 12.81% |
| Capital Expenditure | 14.29% | 38.07% | 47.09% | 77.22% | 84.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,300.00% | 289.87% | -80.76% | -92.76% | -105.18% |
| Cash from Investing | 1,411.11% | 280.53% | -83.91% | -95.07% | -110.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.06% | -87.95% | -87.72% | 1.03% | 0.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5,500.00% | -100.00% | -- | 1,009.75% | 25,100.00% |
| Cash from Financing | 19.80% | -88.06% | -86.78% | 2.68% | 2.80% |
| Foreign Exchange rate Adjustments | 300.00% | 157.66% | 492.45% | 129.67% | -532.90% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 820.00% | -32.94% | -178.77% | -44.72% | -142.79% |